Anzeige
Mehr »
Login
Montag, 27.09.2021 Börsentäglich über 12.000 News von 673 internationalen Medien
Breaking News: TAAT Global verdoppelt die Anzahl der Shops auf 1.000!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
297 Leser
Artikel bewerten:
(1)

Med7 LLC, announce the completion of a safety and efficacy study using Hempzorb81TM Full Spectrum Hemp Oil in patients with Type II Diabetes

BLUFFDALE, Utah, May 4, 2021 /PRNewswire/ -- Med7, LLC (www.Med7cbd.com) and HempCo, Inc. announce the completion of a human clinical study in patients with Type II Diabetes using Purzorb technology, now trademarked as Hempzorb81TM. "This study will provide our customers and providers with evidence based products not seen to this point in the Industrial Hemp and CBD market place," said Matt Smith, CEO of Med7. This study was done with support from the National Institutes of Health (NIH) as part of their small business grant program.

#1 Full Spectrum Hemp Oil Brand Doctors Recommend.

In this placebo-controlled study on 150 patients with Type II Diabetes, Hempzorb81TM demonstrated a significant effect on lowering the A1c with an average drop of 1.2 points versus placebo over six-months. Patients on Hempzorb81TM also lost an average of 14 lbs. and reduced their girth by 4 inches over placebo (www.hempzorb81.org).

Cannabidiol (CBD) alone or in combination with other cannabinoids has never shown a proven clinical effect in glucose management in large placebo-controlled studies. "A naturally occurring whole plant extract with multiple cannabinoids and other natural components can have strong entourage effects on cannabinoid receptors if they can get into the blood stream effectively," according to Paul Murray, CEO of HempCo. "These studies should give consumers and providers confidence that there are hemp products containing CBD that are backed by human clinical studies."

Med7 also received support from the NIH with two other studies: The effect of Hempzorb81TM in Sleep Cycles and in patients with COVID-19. "The study in COVID-19 patients was serendipitous to our Diabetes study and the pandemic. In the first few months of this clinical trial, COVID-19 hit the study group hard," said Smith. "None of the study subjects with COVID-19 dropped out of the study or were hospitalized so we studied these patients more closely. We are evaluating these results and hope to release them soon."

About Med7

Med7 is a technology-driven health and wellness company that distributes full spectrum hemp CBD oil products using Purzorb to medical professionals. Purzorb is a patent pending technology that mimics the body's natural process of absorption by converting oil-based nutrients into water-soluble products.

Logo - https://mma.prnewswire.com/media/1500134/MED_7_Logo.jpg

Kostenloser Wertpapierhandel auf Smartbroker.de
© 2021 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.